Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of the company, received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for SHR-1139 injection, and will conduct clinical trials for palmoplantar impetigo in the near future.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, Guangdong Hengrui Pharmaceutical Co., Ltd., a subsidiary of the company, received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for SHR-1139 injection, and will conduct clinical trials for palmoplantar impetigo in the near future.